STATE OF VASOREGULATORY FUNCTION OF THE ENDOTHELIUM IN PATIENTS WITH PSORIATIC ARTHRITIS
DOI:
https://doi.org/10.11603/1811-2471.2023.v.i1.13390Keywords:
psoriatic arthritis, endothelial dysfunction, endothelium-dependent vasodilationAbstract
SUMMARY. Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints that develops in patients with psoriasis. Mortality among patients with PsA is 1.28 times higher than population levels and in most cases it is caused by cardio-vascular (CV) diseases. The presence of a long-term systemic inflammatory process is a strong predictor of the development of CV diseases due to the development of endothelial dysfunction (ED). It’s well studied in patients with rheumatoid arthritis, ankylosing spondylitis, at the same time, this problem is little discussed and studied in patients with PsA.
The aim – to study the prevalence of endothelial dysfunction and establish its relationship with the activity of the inflammatory process and the degree of skin damage in patients with PsA.
Material and Methods. 97 patients with a diagnosis of PsA were examined, and a control group was formed from 30 clinically healthy patients. All patients underwent diagnostic methods characterizing the course of the disease, assessment of endothelium-dependent vasodilatation (EDVD) in response to reactive hyperemia. The clinical activity of the disease was determined by DAPSA index, the severity and prevalence of psoriasis – PASI.
Results. The results of the study of the function of the endothelium proved that the remodulation of the vessel occurred due to EDVD in response to reactive hyperemia and demonstrated a reliable difference in the most of the investigated parameters between the control group and the examined patients; Significant associations were found that made it possible to establish the dependence of ED on the duration of the disease (r=-0.71, p<0.001), the activity of the disease (r=-0,69, p<0.001), CRP (r=-0.61, p<0.001), PASI (r=-0.42, p<0.001).
Conclusions. We must assume that ED was present in 75 % patients. Significantly higher values of the duration of the disease and significant differences in its course are recorded according to the indicators of VAS, SRP, SOE, DAPSA, PASI indices. The obtained data confirm the hypothesis of interdependence of long-term chronic inflammation and endothelial dysfunction and are consistent with literature data.
References
Singh, J.A., Guyatt, G., Ogdie, A., Gladman, D.D., Deal, C., Deodhar, A., & Reston, J. (2019). 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Journal of Psoriasis and Psoriatic Arthritis, 4(1), 31-58. DOI: https://doi.org/10.1177/2475530318812244
Ocampo, V., & Gladman, D. (2019). Psoriatic arthritis. F1000Research, 8. DOI: https://doi.org/10.12688/f1000research.19144.1
Armstrong, E.J., Harskamp, C.T., & Armstrong, A.W. (2013). Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. Journal of the American Heart Association, 2(2), e000062. DOI: https://doi.org/10.1161/JAHA.113.000062
Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C., Catapano, A.L., Cooney, M.T., … Richter, D. J. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 37(29), 2315-2381. DOI: https://doi.org/10.1093/eurheartj/ehw106
Zheng, Z., Guo, Q., Ma, D., Wang, X., Zhang, C., Wang, H., ... & Zhang, G. (2022). Related Risk Factors and Treatment Management of Psoriatic Arthritis Complicated With Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 9. DOI: https://doi.org/10.3389/fcvm.2022.835439
Papagoras, C., Markatseli, T.E., Saougou, I., Alamanos, Y., Zikou, A. K., Voulgari, P.V., ... & Drosos, A.A. (2014). Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine, 81(1), 57-63. DOI: https://doi.org/10.1016/j.jbspin.2013.03.019
Smiyan, S.I., Koshak, B.O., & Gnatko, I.V. (2017). Endothelial dysfunction and cardiovascular risk in patients with ankylosing spondylitis. International Journal of Medicine and Medical Research, 3(2), 5-9. DOI: https://doi.org/10.11603/ijmmr.2413-6077.2017.2.7935
Castellon, X., & Bogdanova, V. (2016). Chronic inflammatory diseases and endothelial dysfunction. Aging and Disease, 7(1), 81. DOI: https://doi.org/10.14336/AD.2015.0803
Tuleta, I., França, C.N., Wenzel, D., Fleischmann, B., Nickenig, G., Werner, N., & Skowasch, D. (2015). Intermittent hypoxia impairs endothelial function in early preatherosclerosis. Advances in Experimental Medicine and Biology, 858, 1-7. DOI: https://doi.org/10.1007/5584_2015_114
Vanhoutte, P. M., Shimokawa, H., Tang, E. H., & Feletou, M. (2009). Endothelial dysfunction and vascular disease. Acta Physiologica, 196(2), 193-222. DOI: https://doi.org/10.1111/j.1748-1716.2009.01964.x
Koshak, B.O. (2017). Vmist tsyrkylyuyuchuh endotelialnuh klitun v krovi yak marker endotelialnoi dysfynkzii v pazientiv z ankilozuvmum sponduloartritom. [Serum levels of circulating endothelial cells as a marker of endothelial dysfunction in patients with ankylosing spondylitis]. J. Clin. Exp. Med. Res., 5(3), 957-963 [in Ukrainian].
Mauro, D., & Nerviani, A. (2018). Endothelial dysfunction in systemic lupus erythematosus: pathogenesis, assessment and therapeutic opportunities. Reviews on Recent Clinical Trials, 13(3), 192-198. DOI: https://doi.org/10.2174/1574887113666180314091831
Harkevych, T. (2012). Endothelium dependent and endothelium independent regulation of vessels in patients with systemic lupus erythematosus with the classic risk factors of atherosclerosis. Ukrayinskyy naukovo-medychnyy molodizhnyy zhurnal – Ukrainian Scientific and Medical Youth Magazine, 3(69), 94-96.
Peluso, R., Caso, F., Tasso, M., Ambrosino, P., Dario Di Minno, M.N., & Lupoli, R. (2018). Cardiovascular risk markers and major adverse cardiovascular events in psoriatic arthritis patients. Reviews on Recent Clinical Trials, 13(3), 199-209. DOI: https://doi.org/10.2174/1574887113666180314105511
Brezinski, A.E., Follansbee, M., Armstrong, J., & Armstrong, A. (2014). Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Current Pharmaceutical Design, 20(4), 513-528. DOI: https://doi.org/10.2174/138161282004140213123852
Gonzalez-Juanatey, C., Llorca, J., Miranda-Filloy, J.A., Amigo-Diaz, E., Testa, A., Garcia-Porrua, C., ... & Gonzalez-Gay, M.A. (2007). Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Care & Research, 57(2), 287-293. DOI: https://doi.org/10.1002/art.22530
Francis, A.A., & Pierce, G.N. (2011). An integrated approach for the mechanisms responsible for atherosclerotic plaque regression. Experimental & Clinical Cardiology, 16(3), 77.
Moll, J.M.H., & Wright, V. (1973). Psoriatic arthritis. In Seminars in arthritis and rheumatism, 3(1), 55-78. DOI: https://doi.org/10.1016/0049-0172(73)90035-8
Celermajer, D.S., Sorensen, K.E., Gooch, V.M., Spiegelhalter, D.J., Miller, O.I., Sullivan, I.D., ... Deanfield, J. (1992). Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 340(8828), 1111-1115. DOI: https://doi.org/10.1016/0140-6736(92)93147-F
Sharma, A., Reddy, M.H., Sharma, K., Dogra, S., & Vijayvergiya, R. (2016). Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery. International Journal of Rheumatic Diseases, 19(3), 300-304. DOI: https://doi.org/10.1111/1756-185X.12336
Łosińska, K., Korkosz, M., & Kwaśny-Krochin, B. (2019). Endothelial dysfunction in patients with ankylosing spondylitis. Reumatologia/Rheumatology, 57(2), 100-105. DOI: https://doi.org/10.5114/reum.2019.84815
Tiwari, V., & Brent, L.H. (2022). Psoriatic Arthritis. Treasure Island (FL): StatPearls Publishing. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK547710/.
Ritchlin, C.T., Colbert, R.A., & Gladman, D.D. (2017). Psoriatic arthritis. New England: Journal of Medicine, 376(10), 957-970. DOI: https://doi.org/10.1056/NEJMra1505557
Gudu, T., & Gossec, L. (2018). Quality of life in psoriatic arthritis. Expert Review of Clinical Immunology, 14(5), 405-417. DOI: https://doi.org/10.1080/1744666X.2018.1468252
Augustin, M., Krüger, K., Radtke, M.A., Schwippl, I., & Reich, K. (2008). Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology, 216(4), 366-372. DOI: https://doi.org/10.1159/000119415
Smolen, J.S., Schöls, M., Braun, J., Dougados, M., FitzGerald, O., Gladman, D.D., ... & Van Der Heijde, D. (2018). Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the rheumatic diseases, 77(1), 3-17. DOI: https://doi.org/10.1136/annrheumdis-2017-211734corr1
Allanore, Y., Bozzi, S., Terlinden, A., Huscher, D., Amand, C., Soubrane, C., ... & Distler, O. (2020). Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Research & Therapy, 22(1), 1-11. DOI: https://doi.org/10.1186/s13075-020-02329-2
Stanislavchuk, M.A., Orlova, I.V., & Gunko, I.P. (2017). Kros-kulturalna adaptatsiya ta validyzatsiya ukrayinomovnoyi versiyi gout impact scale [Cross-cultural adaptation and validation ukrainian version of gout impact scale]. Ukrainskyi revmatolohichnyi zhurnal – Ukrainian Rheumatological Journal, 4(70), 42-46 [in Ukrainian].
Shen, J., Shang, Q., & Tam, L.S. (2016). Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Translational Research, 167(1), 138-151. DOI: https://doi.org/10.1016/j.trsl.2015.05.006
Järvisalo, M.J., Juonala, M., & Raitakari, O.T. (2006). Assessment of inflammatory markers and endothelial function. Current Opinion in Clinical Nutrition & Metabolic Care, 9(5), 547-552. DOI: https://doi.org/10.1097/01.mco.0000241663.00267.ae
Koshak, B.O., & Smiian, S.I. (2018). Substantiation of necessity and evaluation of endothelial dysfunction correction efficiency in patients with ankylosing spondylitis. Ukrainskyi medychnyi chasopys – Ukrainian Medical Journal, 3(1), 93-96.
Anyfanti, P., Margouta, A., Goulas, K., Gavriilaki, M., Lazaridou, E., Patsatsi, A., & Gkaliagkousi, E. (2022). Endothelial Dysfunction in Psoriasis: An Updated Review. Front. Med. (Lausanne), 10(9), 864185. DOI: https://doi.org/10.3389/fmed.2022.864185
